United Therapeutics Corp. (UTHR) announced Monday morning that it received a second complete response letter from the FDA, declining to approve its new drug application for treprostinil diolamine extended release tablets, for the treatment of pulmonary arterial hypertension.
United Therapeutics gapped open sharply lower Monday, but recovered some ground in early trade, before settling into a range. The stock closed down by 1.33 at $59.62 on strong volume. Shares slipped to over a 3-week low.
For comments and feedback: editorial@rttnews.com